0867 (0867) Fair Value & Analysis

Healthcare · Market cap HK$25.0B

0 0867 0867 · HK

PriceHK$10.28

Fair ValueHK$12.70

Upside+23.5%

Quality51/100

Evidence: High Range HK$6.95 – HK$16.15

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −2.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$9.93 – HK$15.27 · fair‑value band HK$6.95 – HK$16.15 · the HK$10.28 price screens below the HK$12.70 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0867 (0867) currently trades at HK$10.28, while our model-based Fair Value estimate is HK$12.70 — implying the stock looks roughly 23.5% undervalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 0867 generated revenue of HK$8.2B at a net margin of 18.1%. Revenue grew 9.1% year over year. It earns a return on equity of 8.5%. The balance sheet holds a net cash position of HK$2.0B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$8.2B

Revenue growth (YoY) +9.1%

Net margin 18.1%

Return on equity 8.5%

Free cash flow HK$244M FY2025

P/E ratio 14.5

More key figures

Operating margin 17.7%

EPS (TTM) HK$0.3900

Dividend yield 2.8%

EPS growth (YoY) -22.9%

Net cash HK$2.0B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0867 reported revenue of HK$8.2B in FY2025 versus HK$8.3B in FY2021, a compound −0.4%/yr. Reported net income was HK$1.5B in FY2025, compounding −16.2%/yr from FY2021.

Revenue −0.4%/yr

FY21 HK$8.3B

FY22 HK$9.2B

FY23 HK$8.0B

FY24 HK$7.5B

FY25 HK$8.2B

Net income −16.2%/yr

FY21 HK$3.0B

FY22 HK$3.3B

FY23 HK$2.4B

FY24 HK$1.6B

FY25 HK$1.5B

Is 0867 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.01	¥26.59	-43%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.58	HK$18.75	-37%
Divi's Laboratories Limited DIVISLAB	₹6,788	₹2,035	-70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0867 (0867) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$12.70 versus a price of HK$10.28 — about +24% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 0867?

Our model-based fair value for 0867 is HK$12.70 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$10.28.

What is the quality score of 0867?

0867 has a Quality Score of 51/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0867 (0867)?

0867 reported trailing-twelve-month revenue of about HK$8.2B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0867?

The net profit margin of 0867 is about 18.1%, meaning it keeps roughly 18.1% of revenue as net income. Based on the latest reported figures.

Does 0867 pay a dividend?

0867 currently shows a dividend yield of about 2.77% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.